13362-94-2

Usage

Uses

Used in Pharmaceutical Industry:
2-[4-(2-methylpropoxy)phenyl]acetic acid is used as a nonsteroidal anti-inflammatory drug (NSAID) for its potential to alleviate inflammation and pain. The presence of the acetic acid moiety, a characteristic feature of many NSAIDs, suggests that 2-[4-(2-methylpropoxy)phenyl]acetic acid could be effective in reducing inflammation and providing analgesic effects.
The propoxy group in the phenyl ring may also contribute to the compound's unique pharmacological profile, potentially enhancing its efficacy, selectivity, or reducing side effects compared to traditional NSAIDs. This makes it a promising candidate for further research and development in the pharmaceutical industry, with the aim of creating novel therapeutic agents for the treatment of various inflammatory conditions and pain management.
Further exploration into the compound's pharmacological properties, safety, and efficacy will be essential to determine its suitability for clinical use and to establish its place among existing NSAIDs.

Upstream product

• 78-77-3 Isobutyl bromide 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 156-38-7 4-hydroxyphenylacetate 

Downstream Products

• 706779-91-1 N-(1-methylpiperidin-4-yl)-N-(4-fluorophenylmethyl)-N′-(4-(2-methylpropyloxyl)phenylmethyl)carbamide 
• 639863-90-4 2-[4-(2-methylpropoxy)phenyl]acetyl chloride 
• 14794-52-6 N-hydroxy-2-(4-isobutoxyphenyl)acetamide 
• 706782-28-7 Pimavanserin tartrate 
• 5100-04-9 2-(4-Isobutoxyphenyl)acetamide 
• 4734-09-2 1-[4-(2-methylpropyloxy)phenyl]methanamine 
• 500547-95-5 2-[4-(2-methylpropoxy)phenyl]ethan-1-ol 
• 639863-76-6 N-(4-fluorobenzyl)-N-[1-(trifluoroacetyl)piperidin-4-yl]-N'-(4-isobutyloxybenzyl)carbamide 
• 639863-77-7 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(piperidin-4-yl)urea 
• 1370698-61-5 C₂₇H₃₀F₂N₄O₂ 
• 639863-75-5 1-(isocyanatomethyl)-4-(2-methylpropoxy)benzene 

Relevant academic research and scientific papers

Discovery of novel aldose reductase inhibitors characterized by an alkoxy-substituted phenylacetic acid core

In continuation of our effort aimed towards the development of novel aldose reductase inhibitors, several phenylacetic acids bearing an alkoxy substituent in position 3 or 4, respectively, were prepared and screened. The latter represent formal ring openi

COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES

The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.

PROCESS FOR THE MANUFACTURING OF PIMAVANSERIN

The present invention relates to a new process for manufacturing 1 -(4-fluorobenzyl)-3-(4-iso- butoxyphenyl)-1 -(1 -methylpiperidin-4-yl)urea, with the INN name pimavanserin, and its hemi- tartrate salt. Said process comprises the following step: contacting 2-(4-isobutoxyphenyl)acetic acid with N-(4-fluorobenzyl)-1 -methylpiperidin-4-amine in the presence of a base and diphe- nylphosphoryl azide (DPPA) to obtain pimavanserin.

Synthesis method of 4-isobutoxy benzylamine

The invention discloses a synthesis method of 4-isobutoxy benzylamine. 4-hydroxyphenylacetic acid serves as a raw material to generate 4-hydroxyphenylacetic acid methylester through an esterificationreaction; 4-hydroxyphenylacetic acid methylester is subjected to a substitution reaction to generate 4-methyl isobutoxyphenylacetic acid, and 4-isobutoxyphenylacetic acid is obtained after the obtained product is hydrolyzed; 4-isobutoxyphenylacetamide is generated through an acylation reaction; and N-(4-hydroxy benzyl)methyl carbamate is generated through a Hofmann degradation reaction, and a target product is obtained through hydrolysis. The raw materials used in the synthesis method are cheap and easy to get, the reaction condition is mild, post-treatment is simple, column chromatography isnot needed, the product can be obtained easily, and the yield is higher.

PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN

The present disclosure relates to novel, safe and efficient processes for the synthesis of Pimavanserin and salts thereof, as well as novel intermediates that can be used in these processes.

Preparation method of 5-HT2A inverse agonist ACP-103

The invention discloses a preparation method of 5-HT2A inverse agonist ACP-103. The method includes: in the presence of borohydride, subjecting 4-fluorobenzylamine and N-methyl-4-piperidone to reaction to obtain a compound as shown in the formula 3; in the presence of inorganic base, subjecting methyl 4-hydroxyphenylacetate and 1-bromo-2-methylpropane to reaction to obtain a compound as shown in the formula 6; subjecting the compound as shown in the formula 6 to reaction with inorganic base to obtain a compound as shown in the formula 7; subjecting the compound as shown in the formula 7 to reaction with an acyl chloride reagent to obtain a compound as shown in the formula 8; in the presence of tetrabutylammonium bromide, subjecting the compound as shown in the formula 8 to reaction with sodium azide to obtain a compound as shown in the formula 9; subjecting the compound as shown the formula 9 and the compound as shown in the formula 3 to reaction to obtain the compound ACP-103 as shown in the structural formula. The preparation method of the 5-HT2A inverse agonist ACP-103 is mild in reaction condition and high in yield.

An example of designed multiple ligands spanning protein classes: Dual MCH-1R antagonists/DPPIV inhibitors

A ligand-based approach to identify potential starting points for a dual MCH-1R antagonist/DPPIV inhibitor medicinal chemistry program was undertaken. Potential ligand pairs were identified by analysis of MCH-1R and DPPIV in vitro data. A highly targeted

N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS

Disclosed herein are isolated forms of the compounds of Formula (I), (II), (III), (IV) and (V), or a pharmaceutically acceptable salt, prodrug, hydrate, solvate, polymorph, or ester thereof. Also disclosed are methods of inhibiting an activity of a serotonin receptor, methods inhibiting an activation of a serotonin receptor, and methods of alleviating or treating various disease conditions and side effects.

SUBSTITUTED UREAS

Disclosed herein are urea-based 5-HT receptor modulators, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of 5-HT receptor-mediated disorders.

USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS

Inverse agonists and antagonists of serotonin receptors are disclosed for use in treating sleep disorders such as insomnia, and specifically sleep maintenance insomnia. The compound increase slow wave sleep, decrease the number of awakenings after sleep onset, and decrease the time awake after sleep onset.